A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Abroad (travel likely)RecruitingPHASE1
Conditions
Relapsed and/or Refractory Mature T Cell Malignancy · Peripheral T-Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Hepatosplenic T-cell Lymphoma · Monomorphic Epithelialtropic Intestinal Lymphoma · Enteropathy Associated T-cell Lymphoma · Cutaneous T-Cell Lymphoma · Mycosis Fungoides · Subacute Panniculitis-like T-cell Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (National Cancer Institute Referral Office) · ncimo_referrals@mail.nih.gov · 888-624-1937
Study leads
Samuel Y Ng, M.D.
Principal Investigator
National Cancer Institute (NCI)